FBIO — Fortress Biotech, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1429260 ·
Last close
$2.17
Market Cap
$72.37M
52W High
$4.53
52W Low
$2.17
ADV30
341,507
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 18,718,000 | 12,575,000 | -10,006,000 | -468,000 | 316,715,000 | 196,576,000 | 110,629,000 |
| Mar 2026 | 16,038,000 | 9,820,000 | -7,739,000 | 110,373,000 | 356,874,000 | 255,841,000 | 154,500,000 |
| Dec 2025 | 16,079,000 | 10,639,000 | -4,789,000 | -3,937,000 | 185,548,000 | 79,381,000 | 123,365,000 |
| Sep 2025 | 17,631,000 | 11,876,000 | -6,811,000 | 5,850,000 | 181,407,000 | 86,218,000 | 116,222,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$157,637,000
Investing CF
$8,956,000
Financing CF
$-2,091,000
CapEx
—
Dividends Paid
$-498,000
Buybacks
$-14,450,000
EPS Diluted TTM
$2.90
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-623,679,000
Inventory
$9,292,000
Receivables
$25,508,000
ST Investments
—
EBIT TTM
$141,245,000
Pretax Income TTM
$133,280,000
Interest Exp TTM
$7,965,000
Analysts
2
Yahoo Snapshot (yfinance, live)
Total Revenue
$68,466,000
EBITDA
$-24,979,000
Free Cash Flow
$-17,136,250
Enterprise Value
$-17,266,498
Total Cash
$196,576,000
Total Debt
$53,316,000
Shares Out
33,350,993
Trailing EPS
$2.77
Book Value
$4.93
ROE
116.0%
ROA
-7.8%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 63,262,000 | -70,221,000 | 6,815,000 | 185,548,000 | 123,365,000 | 49,873,000 | -65,777,000 |
| Dec 2024 | 57,675,000 | -111,240,000 | -45,997,000 | 144,223,000 | 145,867,000 | 22,737,000 | -80,191,000 |
| Dec 2023 | 84,513,000 | -139,199,000 | -60,637,000 | 167,526,000 | 165,939,000 | 22,544,000 | -128,225,000 |
| Dec 2022 | 75,743,000 | -203,564,000 | -86,575,000 | 294,301,000 | 244,276,000 | 41,721,000 | -179,401,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.76
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| PMVP | PMV Pharmaceuticals, Inc. | $72.70M | $1.36 | — |
| MAIA | MAIA Biotechnology, Inc. | $71.78M | $1.18 | — |
| GOSS | Gossamer Bio, Inc. | $70.39M | $11.52 | — |
| CING | Cingulate Inc. | $70.09M | $4.82 | — |
| ALDX | Aldeyra Therapeutics, Inc. | $69.98M | $1.16 | — |
News headlines (Yahoo Finance, 1h cache)
Fortress Biotech (FBIO) Q2 2026 Earnings Call Transcript
2026-08-14 02:28 · Yahoo
Fortress Biotech Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
2026-08-13 20:05 · Yahoo
Fortress Biotech Q2 Earnings Call Highlights
2026-08-12 23:04 · Yahoo
Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics’ $130 Million Series B Financing
2026-07-27 12:00 · Yahoo
Fortress Biotech to Participate in the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference
2026-05-04 12:30 · Yahoo
Fortress Biotech’s Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 Million
2026-03-30 20:05 · Yahoo
Fortress Biotech Reports 2025 Financial Results and Recent Corporate Highlights
2026-03-31 20:05 · Yahoo
Journey Medical (DERM) Stock Draws Fresh Price Target Split After Fortress Valuation Changes
2026-06-25 04:29 · Yahoo
Journey Medical Corporation to Participate in September 2026 Investor Conferences
2026-09-08 20:05 · Yahoo
Fortress Biotech to Present at the H.C. Wainwright 28th Annual Global Investment Conference
2026-09-08 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.